Coloplast A/s Class B · OMXCOP:COLO_B

Coloplast A/s Class B — Q1 2017/18 Earnings Presentation

7 slides from Coloplast A/s Class B's earnings presentation, Feb 1, 2018

  1. Slide 1: Coloplast Earnings Conference Call Q1 2017/18

    Coloplast Earnings Conference Call Q1 2017/18 1 February 2018

  2. Slide 2: Forward-looking statements

    Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements

  3. Slide 3: Coloplast delivered Q1 organic growth of 8% and an EBIT margin of 31%

    Coloplast delivered Q1 organic growth of 8% and an EBIT margin of 31% Q1 Highlights • Organic revenue growth of 8% (5% in DKK) Revenue growth +8% • Negative impact from USD and USD related currencies Reported revenue (DKKm) +5% • Strong underlying growth in US Chronic Care even when adjusting for th

  4. Slide 4: Strong growth in all business areas except Wound Care due to price reforms in Greece

    Strong growth in all business areas except Wound Care due to price reforms in Greece Q1 17/18 revenue by business area Q1 17/18 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area DKKm growth area DKKm growth

  5. Slide 5: EBIT in constant currencies grew 4% in Q1 2017/18

    EBIT in constant currencies grew 4% in Q1 2017/18 Comments EBIT margin development (%) • EBIT fell 2% to DKK 1,207m with a reported margin of 31% 32.6 (31% in constant currencies) compared to 33% last year -1.3 • Gross margin of 67% compared to 69% same period last 31.1 year -1.3 30.5 0.6 • Negative

  6. Slide 6: Updated reported growth guidance for 17/18

    Updated reported growth guidance for 17/18 Guidance 17/18 Guidance 17/18 (DKK) Key assumptions • DKK 100m patent expiry • More than 1% negative price pressure of which DKK Sales growth ~7% (organic) 5-6% 100m from price reform in Greece • DKK guidance includes Comfort Medical in Q1 and Lilial in Q2-

  7. Slide 7: Our mission, values and vision

    Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast A/S - Ostomy Care / C

Coloplast — Q1 2017/18 Earnings Presentation on 6ix